Friday, October 7
Home>>Covid-19>>Oral Covid-19 Vaccine on the way
oral
Covid-19New Launch

Oral Covid-19 Vaccine on the way

Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, with Oramed Pharmaceuticals, announced the development of an oral Covid-19 vaccine that has shown efficacy after a single dose.

Premas, Oramed and other shareholders, have formed Oravax Medical, which has received exclusive licenses from Oramed and Premas to develop oral COVID-19 vaccines.

After a single dose of the Oravax COVID-19 capsule, efficacy was evident through antibody production in a pilot animal study. Oravax’s vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protect against viral infections and Immunoglobulin A (IgA) protects the respiratory and gastrointestinal tracts against infection. Premas’
protein-based VLP (virus-like particle) vaccine candidate creates triple protection against the SARS CoV-2 virus spike, membrane, and envelope targets.

The vaccine candidate is also safe, efficacious and well-tolerated at normal to high doses, and generated high titres of neutralizing antibodies.

The VLP is manufactured using Premas’ proprietary D-Crypt platform, which is highly scalable and can be manufactured on large scales. An oral Covid-19 vaccine that harnesses and combines the true potential of Premas’ D-Crypt technology platform with Oramed’s world-leading oral protein delivery platform, POD is an excellent example of collaboration and can rapidly advance into late-stage clinical trials, says Dr Prabuddha Kundu, Premas Biotech Co-Founder and Managing Director.

Oramed’s experience and success in conducting Phase 2 and 3 oral protein trials position its program favourably in the race to find an effective oral Covid-19 vaccine that can be administered by anyone anywhere. The company is expected to share clinical data soon. An oral COVID19 vaccine would eliminate several barriers to rapid, wide-scale distribution, enabling people to take the vaccine themselves at home, says Nadav Kidron, CEO of Oramed.

close

Oh hi there 👋
It’s nice to meet you.

Join our mailing list to receive the latest news and updates from Ecostar Business Online Magazine.

After subscribing, check your inbox or spam folder to confirm your subscription.



Share this article:

By Heart - Sajikumar Nair

Leave a Reply

Your email address will not be published. Required fields are marked *